Società Xeris Biopharma Holdings, Inc. Nasdaq
Azioni
XERS
US98422L1070
Prodotti farmaceutici
Attività
Numero di dipendenti: 377
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Gvoke, Keveyis and Recorlev
93,6
%
| 109 | 99,1 % | 153 | 93,6 % | +40,36% |
Royalty, Contract and Other
6,4
%
| 1 | 0,9 % | 11 | 6,4 % | +971,07% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 110 | 100,0 % | 164 | 100,0 % | +48,68% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Founder | 60 | 01/01/05 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 05/10/21 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 01/01/21 |
John Shannon
PSD | President | 62 | 05/10/21 |
Ken Johnson
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/10/21 |
Allison Wey
IRC | Investor Relations Contact | - | - |
Kevin McCulloch
PRN | Corporate Officer/Principal | - | 01/10/18 |
Beth Hecht
LAW | General Counsel | 60 | 01/10/21 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 05/10/21 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 05/10/21 |
Marla Persky
BRD | Director/Board Member | 68 | 05/10/21 |
Paul Edick
CEO | Chief Executive Officer | 67 | 05/10/21 |
Garheng Kong
BRD | Director/Board Member | 49 | 01/10/21 |
John Schmid
BRD | Director/Board Member | 60 | 05/10/21 |
Director/Board Member | 65 | 05/10/21 | |
Dawn Halkuff
BRD | Director/Board Member | 53 | 05/10/21 |
Ricki Fairley
BRD | Director/Board Member | 67 | 27/03/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 148 253 615 | 142 712 322 ( 96,26 %) | 0 | 96,26 % |
Coordinate società
Xeris Biopharma Holdings, Inc.
1375 West Fulton Street Suite 1300
60607, Chicago
+
http://www.xerispharma.comSettore
Vendite per attività
Variaz. 1 gen. | Capi. | |
---|---|---|
+25,83% | 661 Mrd | |
+27,00% | 566 Mrd | |
-6,76% | 352 Mrd | |
+20,34% | 332 Mrd | |
+3,00% | 283 Mrd | |
+13,09% | 231 Mrd | |
+5,46% | 200 Mrd | |
-9,61% | 195 Mrd | |
-6,26% | 145 Mrd |